Is bone mineral density predictive of fracture risk reduction?

References

• Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7:390–406
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Osteoporosis: Physician’s Guide to Prevention and Treatment of Osteoporosis. Belle Meade, NJ: Excerpta Medica; 1999
   Google Scholar
• Nelson HD, Helfand M, Woolf SH, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529–41
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1–129
   PubMed Web of Science ®Google Scholar
• Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1–34
   Google Scholar
• Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368–81
   PubMed Web of Science ®Google Scholar
• Chesnut CH, 3rd, Rose CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001;16:2163–72
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231–6
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109:267–76
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• Eastell R, Watts NB. Osteoporosis: consider the outcomes. Available at: http://www.medscapel.com/viewprogram/1640_pnt. Accessed July 10, 2002
   Google Scholar
• Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001;20:3175–88
   PubMed Web of Science ®Google Scholar
• Watts N, Bockman R, Smith C, et al. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients [abstract]. Osteoporos Int 2000;11:S203
   PubMed Web of Science ®Google Scholar
• Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002;13:501–5
   PubMed Web of Science ®Google Scholar
• Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140–3
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1–10
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women’s Health Initiative Randomized Trial. JAMA 2003;290:1729–38
   PubMed Web of Science ®Google Scholar
• Miacalcin (R) (calcitonin salmon, Novartis Pharmaceuticals Corporation, East Hanover, NJ). Full prescribing information, 2003
   Google Scholar
• Forteo (R) (teriparatide, Eli Lilly and Company, Indianapolis, IN). Full prescribing information, 2002
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
   PubMed Web of Science ®Google Scholar
• Michelotti J, Clark J. Femoral neck length and hip fracture risk. J Bone Miner Res 1999;14:1714–20
   PubMed Web of Science ®Google Scholar
• Oleksik A, Ott SM, Vedi S, et al. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15:1368–75
   PubMed Web of Science ®Google Scholar
• Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000;15:13–9
   PubMed Web of Science ®Google Scholar
• Borah B, Gross GJ, Dufresne TE, et al. Three-dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec 2001;265:101–10
   PubMedGoogle Scholar
• Majumdar S. A review of magnetic resonance (MR) imaging of trabecular bone micro-architecture: contribution to the prediction of biomechanical properties and fracture prevalence. Technol Health Care 1998;6:321–7
   PubMedGoogle Scholar
• Hyldstrup L, Jorgensen JT, Sorensen TK, et al. Response of cortical bone to antiresorptive treatment. Calcif Tissue Int 2001;68:135–9
   PubMed Web of Science ®Google Scholar
• Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001;29:185–91
   PubMed Web of Science ®Google Scholar
• Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002;17:1139–47
   PubMed Web of Science ®Google Scholar
• Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate (RIS) preserves trabecular architecture in early postmenopausal women in just 1 year: a paired biopsy study using 3D microct [Abstract P69SU]. Osteoporos Int 2002;13:S25
   Web of Science ®Google Scholar
• Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475–80
   PubMed Web of Science ®Google Scholar
• Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157–65
   PubMed Web of Science ®Google Scholar
• Burr DB, Forwood MR, Fyhrie DP, et al. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997;12:6–15
   PubMed Web of Science ®Google Scholar
• Ahlborg HG, Johnell O, Nilsson BE, et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone 2001;28:327–31
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 1992;13(Suppl 2):S41–7
   PubMedGoogle Scholar
• Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 2002;17:1558–9[discussion 60]
   PubMed Web of Science ®Google Scholar
• Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11:S66–76
   PubMed Web of Science ®Google Scholar
• Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:S2–17
   PubMedGoogle Scholar
• Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85: 3537–40
   PubMed Web of Science ®Google Scholar
• Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363–8
   PubMed Web of Science ®Google Scholar
• Yen ML, Yen BL, Jang MH, et al. Effects of alendronate on osteopenic postmenopausal Chinese women. Bone 2000;27:681–5
   PubMed Web of Science ®Google Scholar
• Delmas PD. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 2002;30:14–7
   PubMed Web of Science ®Google Scholar
• Watts NB, Adami S, Chesnut C. Risedronate reduces the risk of clinical vertebral fractures in just 6 months [abstract]. J Bone Miner Res 2001;16:S407
   Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922–30
   PubMed Web of Science ®Google Scholar